Investment Thesis — Glaukos Corporation
The market is overly focused on Glaukos's current negative EPS, failing to fully price in the long-term growth trajectory of its innovative minimally invasive glaucoma surgery (MIGS) solutions and promising pipeline. This short-sightedness creates an opportunity to acquire a future leader in ophthalmic health at a discount.
Catalysts
- Positive Phase 3 clinical trial results and subsequent regulatory approval for iDose TR.
- Faster-than-anticipated market adoption and reimbursement expansion for new product launches.
- Strategic partnerships or acquisitions that broaden market reach or pipeline.
Risk Factors
- Clinical trial failures or significant delays for key pipeline products.
- Intensified competition from new entrants or existing players in the MIGS market.
- Adverse changes in healthcare reimbursement policies or regulatory landscape.
Key Debates
Fwd Growth Sustains 20.9% by Q4, Re-rating to $143.44
6.8% Short Float Squeezes to $143.44 by Q4 Earnings
Analyst Target $143.44 Proves Accurate by Q1 2025